myirislogo
19 December, 2014 19:45 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 304.25 0.73
Hindalco In 157.65 2.64
Infosys 2001.90 1.81
Icici Bank 355.40 2.95
Tata Stl 405.20 2.99
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Shasun Pharmaceuticals Limited
Shasun Pharmaceuticals Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524552NSE:SHASUNPHARBloomberg:SAPH@INReuters:SHAS.BO
Market Lot: 1Face Value: 2ISIN Demat: INE317A01028
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
19-AUG-14 Shasun Pharmaceuticals said on Tuesday that the company has granted 2,23,000 stock options under Employee Stock Option Plan (ESOP) 2012 to the employees exercisable into same number of equity shares of the company. 08-JUL-14 Shasun Pharmaceuticals has completed both USFDA and Mexican Cofepris (Mexican regulatory authority) inspection at its API facility at Cussalore Tamil Nadu, India. 30-MAY-14 Shasun Pharmaceuticals disclosed a ste...   More..
Business Profile Future Plans
CEO Talk
Shasun Chemicals and Drugs Ltd, while focusing on the bulk drugs business, expects increased contribution from the contract research business. The bulk drugs business, including the biotech sector, will continue to be its major focus in the years to come.   S. Vimal Kumar
One To One
Recent news
Latest News
Strides Arcolab approves merger with Shasun Pharma  -IRIS 29-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 2369.808816.207290.20
Other Income21.80122.70136.60
Total Income2391.608938.907426.80
Cost of goods sold2311.108452.707146.30
OPBDIT80.50486.20280.50
PAT36.60352.30262.80
Gross Block---
Equity capital120.30113.30113.30
EPS (Rs.)-6.224.76
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-7.33 - 15.1412.69 - 39.05
Debt / Equity (x)---
Operating margin (% of OI) 3.4 5.4 3.8
Net margin (% of OI) 1.5 3.9 3.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Batra Centre
28 Sardar Patel Road
3rd and 4th floor
Guindy
Chennai
Tamil Nadu-600 032
PHONE
(044) 4344 6700
FAX
(044) 2235 0924/ 2235 0278
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer